检索结果-南通市图书馆

Indoleamine-2,3-dioxygenase 1/cyclooxygenase 2 expression prediction for adverse prognosis in colorectal cancer

World Journal of Gastroenterology 2018年第20期24卷 2181-2190页

作者： Wen-Juan Ma Xing Wang Wen-Ting Yan zhong-Guo Zhou zhi-zhong pan Gong Chen Rong-Xin Zhang State Key Laboratory of Oncology in South China Sun Yat-sen UniversityGuangzhou 510060Guangdong ProvinceChina Collaborative Innovation Center of Cancer Medicine Guangzhou 510060Guangdong ProvinceChina Tongji Medical College Huazhong University of Science and TechnologyWuhan 430074Hubei ProvinceChina Department of Hepatobiliary Surgery Cancer CenterSun Yat-sen UniversityGuangzhou 510060Guangdong ProvinceChina Department of Colorectal Surgery Cancer CenterSun Yat-sen UniversityGuangzhou 510060Guangdong ProvinceChina

AIM To evaluate indoleamine-2,3-dioxygenase 1/cyclooxygenase 2(IDO1/COX2) expression as an independent prognostic biomarker for colorectal cancer(CRC) *** We retrospectively studied the medical records of 95 patients who received surgical resection from August 2008 to January 2010. All patients were randomly assigned to adjuvant treatment with or without celecoxib groups after surgery. We performed standard immunohistochemistry to assess the expression levels of IDO1/COX2 and evaluated the correlation of IDO1/COX2 with clinicopathological factors and overall survival(OS) *** The expression of nuclear IDO1 was significantly correlated with body mass index(P < 0.001), and IDO1 expression displayed no association with sex, age, tumor differentiation, T stage, N stage, carcinoembryonic antigen, cancer antigen 19-9, CD3+ and CD8+ tumor infiltrating lymphocytes, and COX2. In univariate analysis, we found that nuclear IDO1(P = 0.039), nuclear/cytoplasmic IDO1 [hazard ratio(HR) = 2.044, 95% confidence interval(CI): 0.871-4.798, P = 0.039], nuclear IDO1/COX2(HR = 3.048, 95%CI: 0.868-10.7, P = 0.0049) and cytoplasmic IDO1/COX2(HR = 2.109, 95%CI: 0.976-4.558, P = 0.022) all yielded significantly poor OS outcomes. Nuclear IDO1(P = 0.041), nuclear/cytoplasmic IDO1(HR = 3.023, 95%CI: 0.585-15.61, P = 0.041) and cytoplasmic IDO1/COX2(HR = 2.740, 95%CI: 0.764-9.831, P = 0.038) have significantly poor OS outcomes for the CRC celecoxib subgroup. In our multivariate Cox model, high coexpression of cytoplasmic IDO1/COX2 was found to be an independent predictor of poor outcome in CRC(HR = 2.218, 95%CI: 1.011-4.48, P = 0.047) and celecoxib subgroup patients(HR = 3.210, 95%CI: 1.074-9.590, P = 0.037).CONCLUSION Our results showed that cytoplasmic IDO1/COX2 coexpression could be used as an independent poor predictor for OS in CRC.

关键词： Prognosis Indoleamine-2,3-dioxygenase 1 Cyclooxygenase 2 Colorectal cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Oxaliplatin-containing adjuvant chemotherapy improves the survival of locally advanced rectal cancer patients with pathological complete response after pre-operative chemoradiotherapy

引用

Gastroenterology Report 2018年第3期6卷 195-201,I0002页

作者： Jian-Hong Peng Jun-zhong Lin Yu-Ming Rong Ying Zhu Yu-Xiang Deng Yu-Jie Zhao Zhen-Hai Lu Xiao-Jun Wu zhi-zhong pan Department of Colorectal Surgery Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer Medicine651 Dongfeng Road EastGuangzhouGuangdong 510060P.R.China VIP Region Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer Medicine651 Dongfeng Road EastGuangzhouGuangdong 510060P.R.China

Background:The necessity for adjuvant chemotherapy(ACT)in locally advanced rectal cancer(LARC)patients who achieve pathological complete response(pCR)after pre-operative chemoradiotherapy(CRT)is still not *** aimed to investigate the therapeutic value of ACT in these ***:Clinical data were retrospectively collected from 105 consecutive LARC patients who achieved pCR after pre-operative CRT and underwent radical tumor resection between December 2008 and April 2014 in a comprehensive cancer *** chemotherapy(CT)was administered by combining oxaliplatin with capecitabine(XELOX regimen).Disease-free survival(DFS)and overall survival(OS)rates of patients with or without ACT were ***:Eighty-three(79.0%)patients received ACT and 22(21.0%)did *** a median follow-up of 49 months,the ACT group had a significantly higher 3-year DFS rate(92.8 vs 86.4%,p=0.029)and 3-year OS rate(95.1 vs 86.1%,p=0.026)than the non-ACT *** multivariable analyses,the presence of ACT was an independent prognostic factor for DFS(hazard ratio[HR]:0.271;95%confidence interval(CI):0.080–0.916;p=0.036)but not for *** benefit was more obvious in patients younger than 60 years via subgroup analysis(adjusted HR:0.106;95%CI:0.019–0.606;p=0.012).Conclusions:Oxaliplatin-containing ACT may confer survival benefits to patients with pCR,particularly younger ***,the routine use of ACT in patients with pCR needs further validation.

关键词： Adjuvant chemotherapy rectal cancer pre-operative chemoradiotherapy pathological complete response survival

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Programmed death-ligand 1 expression in the tumour stroma of colorectal liver oligometastases and its association with prognosis after liver resection

引用

Gastroenterology Report 2021年第5期9卷 443-450,I0002页

作者： Jian-Hong Peng Yi Tai Yi-Xin Zhao Bao-Jia Luo Qing-Jian Ou zhi-zhong pan Lin Zhang Zhen-Hai Lu Department of Colorectal Surgery Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer Medicine GuangzhouGuangdongP.R.China Department of Clinical Laboratory Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China

Background The clinical value of programmed death-ligand 1(PD-L1)expression in colorectal liver oligometastases(CLOs)remains *** study aimed to detect PD-L1 in the microenvironment of CLOs and determine its association with patient *** We collected 126 liver-resection specimens from CLO patients who underwent curative liver resection between June 1999 and December ***(IHC)was performed to assess PD-L1 expression in paraffinembedded *** survival(OS)and recurrence-free survival(RFS)were analysed using the Kaplan–Meier method and log-rank *** PD-L1 was mainly expressed in the stroma of liver *** with high PD-L1 expression had a higher proportion of clinical-risk scores(CRSs)of 2–4(67.7%vs 40.4%;P=0.004).With a median 58-month follow-up,patients with high PD-L1 expression had a significantly lower 3-year OS rate(65.5%vs 92.7%;P=0.001)and 3-year RFS rate(34.7%vs 83.8%;P<0.001)than patients with low PD-L1 *** Cox analysis demonstrated that high PD-L1 expression(hazard ratio[HR]=3.581;95%confidence interval[CI]2.301–9.972;P=0.015),CRS 2–4(HR=6.960;95%CI 1.135–42.689;P=0.036)and increased preoperative CA19-9(HR=2.843;95%CI 1.229–6.576;P=0.015)were independent risk factors for *** PD-L1 expression(HR=4.815;95%CI 2.139–10.837;P<0.001)and lymph-node metastasis(HR=2.115;95%CI 1.041–4.297;P=0.038)were independent risk factors for *** This study found that PD-L1 was commonly expressed in the tumour stroma of CLOs and high PD-L1 expression was associated with poor prognosis.

关键词： PD-L1 colorectal liver oligometastases expression prognosis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Germline mutational profile of Chinese patients under 70 years old with colorectal cancer

引用

Cancer Communications 2020年第11期40卷 620-632页

作者： Teng-Jia Jiang Fang Wang Ying-Nan Wang Jia-Jia Hu Pei-Rong Ding Jun-zhong Lin zhi-zhong pan Gong Chen Jian-Yong Shao Rui-hua Xu Qi Zhao Feng Wang State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer MedicineDepartment of OncologySun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Molecular Diagnosis Sun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Experimental Research Sun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Colorectal Surgery Sun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China

Background:Inherited susceptibility accounts for nearly one-third of colorectal cancer(CRC)predispositions and has an 80%-100%lifetime risk of this ***,there are few data about germline mutations of hereditary CRC-related genes in Chinese patients with *** study aimed to assess the prevalence of gene mutations related to cancer susceptibility among Chinese patients with CRC,differences between Chinese and Western patients,and the phenotypegenotype ***:We retrospectively collected tumor samples from 526 patients with CRC under 70 years old who underwent hereditary CRC genetic testing.A series of bioinformatic analyses,as well as statistical comparisons,were ***:We found that 77 patients(14.6%)harbored functional variants of the 12 *** mutation frequencies of the top 5 mutated genes were 6.5%for MutL homolog 1(MLH1),5.1%for MutS homolog 2(MSH2),1.0%for MSH6,0.8%for PMS1 homolog 2(PMS2),and 0.8%for APC regulator of the WNT signaling pathway(APC).Our data showed much higher rates of mutations of MSH6 and PMS2 genes among all mismatch repair(MMR)genes as compared with those in Western *** in MLH1,MSH2,and MSH6 were found to be mutually *** with MLH1 or MSH2 mutations had higher frequencies of personal history of cancer(MLH1:20.6%vs.8.7%;MSH2:25.9%vs.8.6%)and family history of cancer than those without these mutations(MLH1:73.5%vs.48.4%;MSH2:70.4%vs.48.9%),and the lesions were more prone to occur on the right side of the colon than on the left side(MLH1:73.5%vs.29.3%;MSH2:56.0%vs.31.0%).The proportion of stage I/II disease was higher in patients with MLH1 mutations than in those without MLH1 mutations(70.6%vs.50.7%),and the rate of polyps was higher in patients withAPC mutations than in those with wild-type APC(75.0%vs.17.4%).Conclusion:These results provide a full-scale landscape of hereditary susceptibility over 12 related genes in CRC patients and suggest that a comprehensive multi-ge

关键词： colorectal cancer genetic testing germline mutation hereditary CRC syndromes

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study

引用

Cancer Communications 2018年第1期38卷 263-271页

作者： Xin Yu Qiao-xuan Wang Wei-wei Xiao Hui Chang zhi-fan Zeng Zhen-hai Lu Xiao-jun Wu Gong Chen zhi-zhong pan De-sen Wan Pei-rong Ding Yuan-hong Gao Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuang-zhouP.R.China Department of Radiation Oncology Sun Yat-sen University Cancer Center651 Dongfeng Rd EastGuangzhou 510060P.R.China Department of Colorectal Surgery Sun Yat-sen University Cancer Center651 Dongfeng Rd EastGuangzhou 510060P.R.China

Background:Neoadjuvant chemoradiotherapy followed by surgery is recommended as the standard of care for locally advanced rectal cancer,reducing local recurrence but not distant *** systemic therapy is warranted to reduce the risk of distant *** present study aimed to evaluate the safety and efficacy of neo-adjuvant oxaliplatin and capecitabine(XELOX)combined with bevacizumab plus radiotherapy for locally advanced rectal ***:Patients with stages II to III rectal cancer received one cycle of induction chemotherapy and concurrent chemoradiotherapy with XELOX plus *** was performed 6-8 weeks after completion of radiotherapy,and postoperative chemotherapy with three cycles of XELOX and two cycles of capecitabine were *** primary endpoints were pathologic complete response(pCR)rate and safety,and the secondary endpoints were 3-year overall survival and progression-free ***:Forty-five patients were enrolled between February 2013 and April *** completed the neoadjuvant *** patients(15.6%)refused subsequent surgical therapy for personal reasons,and the other 38 patients received radical resection,with a sphincter preservation rate of 84.2%and a pCR rate of 39.5%.Toxicity was acceptable,with grades 3-4 hematological toxicity and diarrhea observed in six and two patients,*** of anastomotic leak that required surgical intervention was 13.3%.After a median follow-up period of 37 months,five patients developed disease progression and two died of *** 3-year overall survival rate and 3-year progres-sion-free survival rate were 95.3%and 88.6%,***:The addition of bevacizumab to neoadjuvant chemoradiotherapy resulted in a satisfying pCR rate and 3-year survival,but also may increase the risk of anastomotic leak,thus this regimen is not suitable to be considered for regular recommendation for locally advanced rectal cancer.

关键词： Bevacizumab Neoadjuvant chemoradiotherapy Locally advanced rectal cancer Safety Efficacy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

The loss-of-function mutations and down-regulated expression of ASB3 gene promote the growth and metastasis of colorectal cancer cells

引用

Chinese Journal of Cancer 2017年第1期36卷 11-25页

作者： Wu-Ying Du Zhen-Hai Lu Wen Ye Xiang Fu Yi Zhou Chun-Mei Kuang Jiang-Xue Wu zhi-zhong pan Shuai Chen Ran-Yi Liu Wen-Lin Huang State Key Laboratory of Oncology in South China Collaborative Innovation Center of Cancer Medicine Sun Yat-sen University Cancer Center Department of Radiation Oncology University of Arkansas for Medical Sciences Department of Oncology The First Affiliated Hospital Sun Yat-sen University Department of Radio-chemotherapy Shangrao People’s Hospital Guangdong Provincial Key Laboratory of Tumor-targeted Drug and Guangzhou Enterprise Key Laboratory of Gene Medicine Guangzhou Doublle Bioproducts Co. Ltd.

Background: Ankyrin repeat and SOCS box protein 3(ASB3) is a member of ASB family and contains ankyrin repeat sequence and SOCS box domain. Previous studies indicated that it mediates the ubiquitination and degradation of tumor necrosis factor receptor 2 and is likely involved in inflammatory responses. However, its effects on oncogenesis are unclear. This study aimed to investigate the effects of ASB3 on the growth and metastasis of colorectal cancer(CRC).Methods: We used next?generation sequencing or Sanger sequencing to detect ASB3 mutations in CRC specimens or cell lines, and used real?time quantitative polymerase chain reaction, Western blotting, and immunohistochemical or immunofluorescence assay to determine gene expression. We evaluated cell proliferation by MTT and colony for?mation assays, tested cell cycle distribution by flow cytometry, and assessed cell migration and invasion by transwell and wound healing assays. We also performed nude mouse experiments to evaluate tumorigenicity and hepatic metastasis potential of tumor ***: We found that ASB3 gene was frequently mutated(5.3%) and down?regulated(70.4%) in CRC cases. Knock?down of endogenous ASB3 expression promoted CRC cell proliferation, migration, and invasion in vitro and facilitated tumorigenicity and hepatic metastasis in vivo. Conversely, the ectopic overexpression of wild?type ASB3, but not that of ASB3 mutants that occurred in clinical CRC tissues, inhibited tumor growth and metastasis. Further analysis showed that ASB3 inhibited CRC metastasis likely by retarding epithelial?mesenchymal transition, which was characterized by the up?regulation of β?catenin and E?cadherin and the down?regulation of transcription factor 8, N?cadherin, and ***: ASB3 dysfunction resulted from gene mutations or down?regulated expression frequently exists in CRC and likely plays a key role in the pathogenesis and progression of CRC.

关键词： Ankyrin repeat and SOCS box protein 3(ASB3) Colorectal cancer Epithelial-mesenchymal transition Cell proliferation Tumor metastasis

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Low prevalence of mismatch repair deficiency in Chinese colorectal cancers:a multicenter study

引用

Gastroenterology Report 2020年第5期8卷 399-403,I0003页

作者： Wu Jiang Qiao-Qi Sui Wen-Liang Li Chuan-Feng Ke Yi-Hong Ling Le-En Liao Zhu Zhu Mu-Yan Cai Jun Luo Lin-Lin Mao Hui-zhong Zhang De-Sen Wan zhi-zhong pan Hai-Xing Ju Pei-Rong Ding Department of Colorectal Surgery Sun Yat-sen University Cancer CenterGuangzhouGuangdongP.R.China State Key Laboratory of Oncology in South China GuangzhouGuangdongP.R.China Collaborative Innovation Center for Cancer Medicine GuangzhouGuangdongP.R.China Department of Surgical Oncology First Affiliated Hospital of Kunming Medical UniversityKunmingYunnanP.R.China Department of Gastrointestinal Surgery The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhouGuangdongP.R.China Department of Pathology Sun Yat-sen University Cancer CenterGuangzhouGuangdongP.R.China Department of Colorectal Surgery Zhejiang Cancer HospitalHangzhouZhejiangP.R.China Department of Clinical Genome Center Guangzhou KingMed Diagnostics Group Co.LtdGuangzhouGuangdongP.R.China

Background:Although universal testing for mismatch repair deficiency(dMMR)has been recommended to all colorectal cancer(CRC)patients,related evidence for the Chinese population is ***,we investigated the prevalence and clinicopathological features of dMMR patients in a large Chinese CRC ***:We included 7,373 CRC patients treated at four Chinese medical centers between August 2010 and September ***’baseline characteristics and pathological features were *** clinicopathological features were compared between patients with MLH1/PMS2 deficiency(dMLH1/PMS2)and MSH2/MSH6 deficiency(dMSH2/MSH6).Results:Among the investigated patients,654(8.9%)were identified with dMMR CRCs and,of them,401(61.3%)were males,with a median age of 55 years(range,22-87 years);355(54.3%)had stage II CRC based on American Joint Committee on Cancer 8th *** prevalence of the dMLH1/PMS2 group and the dMSH2/MSH6 group were 51.5%(337/654)and 25.1%(164/654),*** with dMSH2/MSH6 patients,those with dMLH1/PMS2 were older(57 vs 52 years,P<0.001),more likely to be female(45.7%vs 31.5%,P=0.004),prone to having tumors located in the right-hand side of the colon(59.0%vs 47.6%,P=0.015),and less likely to have a family history of tumors(29.7%vs 43.3%,P=0.003).Conclusions:The prevalence of dMMR in Chinese CRC patients was low,especially in the dMLH1/PMS2 *** clinicopathological features were different between dMMR subgroups.

关键词： prevalence mismatch repair deficiency colorectal cancer

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Using p53-immunostained large specimens to determine the distal intramural spread margin of rectal cancer

引用

World Journal of Gastroenterology 2006年第10期12卷 1626-1629页

作者： zhi-zhong pan De-Sen Wan Chang-Qing Zhang Jian-Yong Shao Li-Ren Li Gong Chen zhi-Wei Zhou Fu-Long Wang Department of Abdominal Surgery Cancer Hospital Sun Yat-Sen University Guangzhou 510060 Guangdong Province China

AIM： To determine the distal intramural spread （DIS） margin of rectal cancer.METHODS： Sixty-one p53-positive specimens of rectal cancer were used. After conventional hematoxylin and eosin （H＆E） staining, the DIS margin of rectal cancer in large specimens was examined by immunohistochemistry. The patients were divided into A, B, C, and D groups. After a long-term follow-up, the survival curves of the four groups were estimated using the life table. RESULTS： Fifty-one of the sixty-one cases （83.6%） had DIS. The extent of DIS ranged 0.11-3.5 cm; meanwhile *** of DIS measured by H＆E staining was 0.13 cm. The significant difference was found between the means （t=5.622, P〈0.0001）. Only 1 of 51 patients had DIS greater than 3 cm. The DIS was less than 1.0 cm in most rectal cancer patients. The long-term results indicated that the survival rate of the patients whose DIS was greater than 1.0 cm was lower than that of the patients whose DIS was less than 0.5 cm. CONCLUSION： Rectal cancer patients with DIS greater than 1.0 cm have poor prognosis.

关键词： Rectal cancer Distal intramural spread p53 Immunohistochemistry Large specimen

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases

引用

Chinese Journal of Cancer 2017年第11期36卷 537-547页

作者： Yun Wang Yun-Fei Yuan Hao-Cheng Lin Bin-Kui Li Feng-Hua Wang zhi-Qiang Wang Pei-Rong Ding Gong Chen Xiao-Jun Wu Zhen-Hai Lu zhi-zhong pan De-Sen Wan Peng Sun Shu-Mei Yan Rui-Hua Xu Yu-Hong Li Sun Yat-sen University Cancer Center State Key Laboratory of Oncology in South China Collaborative Innovation Center for Cancer Medicine Guangzhou 510060 Guangdong P. R. China Department of Medical Oncology Sun Yat-sen University Cancer Center Guangzhou 510060 Guangdong P. R. China Department of Hepatobiliary Surgery Sun Yat-sen University Cancer Center Guangzhou 510060 Guangdong P. R. China Department of Colorectal Surgery Sun Yat-sen University Cancer Center Guangzhou 510060 Guangdong P. R. China Department of Pathology Sun Yat-sen University Cancer Center Guangzhou 510060 Guangdong P. R. China

Background: Pathologic response is evaluated according to the extent of tumor regression and is used to estimate the efficacy of preoperative treatment. Several studies have reported the association between the pathologic response and clinical outcomes of colorecal cancer patients with liver metastases who underwent ***, to date, no data from Chinese patients have been reported. In this study, we aimed to evaluate the association between the pathologic response to pre-hepatectomy chemotherapy and prognosis in a cohort of Chinese *** and methods: In this retrospective study, we analyzed the data of 380 liver metastases in 159 *** pathologic response was evaluated according to the tumor regression grade(TRG).The prognostic role of pathologic response in recurrence-free survival(RFS) and overall survival(OS) was assessed using Kaplan-Meier curves with the log-rank test and multivariate Cox models. Factors that had potential influence on pathologic response were also analyzed using multivariate logistic regression and Kruskal-Wallis/Mann-Whitney U ***: Patients whose tumors achieved pathologic response after preoperative chemotherapy had significant longer RFS and OS than patients whose tumor had no pathologic response to chemotherapy(median RFS: 9.9 vs.6.5 months, P = 0.009; median OS: 40.7 vs. 28.1 months, P = 0.040). Multivariate logistic regression and Kruskal-Wallis/Mann-Whitney U tests showed that metastases with small diameter, metastases from the left-side primary tumors,and metastases from patients receiving long-duration chemotherapy had higher pathologic response rates than their control metastases(all P < 0.05). A decrease in the serum carcinoembryonic antigen(CEA) level after preoperative chemotherapy predicted an increased pathologic response rate(P < 0.05). Although the application of targeted therapy did not significantly influence TRG scores of all cases of metastases, the addition of cetuximab to chemoth

关键词： Colorectal cancer Liver metastases Chemotherapy Pathologic response

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Expert opinions on immunotherapy for patients with colorectal cancer

引用

Cancer Communications 2020年第10期40卷 467-472页

作者： Feng Wang Zi-Xian Wang Gong Chen Hui-Yan Luo Dong-Sheng Zhang Miao-Zhen Qiu De-Shen Wang zhi-zhong pan Lin Shen Jin Li Su-Zhan Zhang Rui-Hua Xu Department of Medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdong 510060P.R.China Department of Colorectal Surgery Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhou 510060P.R.China Department of Gastrointestinal Medical Oncology Peking University Cancer HospitalBeijing 100142P.R.China Department of Medical Oncology Tongji University Shanghai East HospitalShanghai 200120P.R.China Department of Surgical Oncology The Second Affiliated Hospital of Zhejiang University School of MedicineHangzhouZhejiang 310009P.R.China

1 BACKGROUND With the rapid development of immune checkpoint inhibitors(ICIs)over the past decades,they have become a major area of interest in the treatment of colorectal cancer(CRC)[1,2].There are evidence pointing that programmed cell death protein-1(PD-1)blockade,alone or in combination with anti-cytotoxic T-lymphocyte-associated protein 4(anti-CTLA4)therapy,achieved durable responses in patients with mismatch repair-deficient(dMMR)or microsatellite instability-high(MSI-H)metastatic CRC(mCRC)[3–6].However,the optimal diagnostic method for detecting dMMR/MSI-H disease as well as the optimal anti-PD-1-based treatment modality still remains controversial in this patient *** addition,for the majority of mCRC cases that are mismatch repair-proficient(pMMR)or microsatellite stable(MSS),the clinical benefits from these agents are generally minimal[3,7],driving extensive research efforts to develop effective combination therapies in this disease ***,investigations of anti-PD-1-based treatments have also been initiated in the nonmetastatic settings of CRC,with some encouraging preliminary evidence[8].Medical oncologists and surgeons from the Committee of Colorectal Cancer of the Chinese Society of Clinical Oncology had a panel discussion on immunotherapy for patients with colorectal cancer during a seminar on June 16,2020,in Guangzhou,***,the expert opinions have been summarized along with relevant clinical evidence(Table 1)to guide real-world treatment decision-making regarding the use of ICIs in patients with CRC.

关键词： summarized initiated opinion

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：